Cara Therapeutics (CARA) and Tvardi Therapeutics Announce Entry into Merger Agreement Dec 18, 2024 07:01AM
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement Dec 18, 2024 07:00AM
Cara Therapeutics (CARA) Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica Did Not Demonstrate Meaningful Clinical Benefit Jun 12, 2024 04:02PM
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica Jun 12, 2024 04:01PM
Cara Therapeutics Reports First Quarter 2024 Financial Results May 13, 2024 04:01PM
View Older Stories

May 6, 2024 07:00AM Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
Apr 2, 2024 07:00AM Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Mar 7, 2024 07:00AM Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
Mar 4, 2024 04:01PM Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Feb 12, 2024 04:01PM Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Jan 22, 2024 07:04AM Cara Therapeutics (CARA) Prioritizes Late-Stage Notalgia Paresthetica Program, Extends Cash Runway into 2026
Jan 22, 2024 07:00AM Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
Dec 18, 2023 07:04AM Cara Therapeutics (CARA) Announces Outcome from Dose-Finding Part A of KIND 1 Study of Oral Difelikefalin
Dec 18, 2023 07:00AM Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
Nov 13, 2023 04:01PM Cara Therapeutics Reports Third Quarter 2023 Financial Results
Nov 2, 2023 07:01AM Cara Therapeutics (CARA) Announces $40M Non-Dilutive Financing Agreement with HealthCare Royalty
Nov 2, 2023 07:00AM Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
Oct 23, 2023 07:00AM Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
Sep 25, 2023 07:01AM Cara Therapeutics (CARA) Announces Approval of KORSUVA IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
Sep 25, 2023 07:00AM Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
Sep 5, 2023 07:00AM Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 7, 2023 04:01PM Cara Therapeutics Reports Second Quarter 2023 Financial Results
Aug 3, 2023 07:01AM Cara Therapeutics (CARA) Appoints Helen M. Boudreau to its Board
Aug 3, 2023 07:00AM Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
Aug 2, 2023 07:00AM Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
Jul 24, 2023 07:00AM Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
Jun 1, 2023 07:00AM Cara Therapeutics to Present at the Jefferies Healthcare Conference
May 18, 2023 05:49AM Cara Therapeutics (CARA) Announces Kapruvia recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
May 18, 2023 02:00AM Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
May 18, 2023 02:00AM Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
May 15, 2023 04:01PM Cara Therapeutics Reports First Quarter 2023 Financial Results
May 1, 2023 07:00AM Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
May 1, 2023 07:00AM Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
Apr 10, 2023 07:00AM Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
Apr 10, 2023 07:00AM Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
Mar 14, 2023 07:00AM Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
Mar 14, 2023 07:00AM Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
Mar 6, 2023 04:01PM Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
Mar 6, 2023 04:01PM Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
Feb 21, 2023 07:00AM Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
Feb 21, 2023 07:00AM Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
Feb 8, 2023 05:01PM Cara Therapeutics (CARA) Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in NEJM
Feb 8, 2023 05:00PM Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
Feb 8, 2023 05:00PM Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
Jan 17, 2023 07:00AM Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
Jan 17, 2023 07:00AM Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
Jan 3, 2023 07:00AM Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Jan 3, 2023 07:00AM Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Nov 29, 2022 07:33AM KemPharm (KMPH) Announces Appointment of Christopher Posner as New Independent Director
Nov 29, 2022 07:30AM KemPharm Announces Appointment of Christopher Posner as New Independent Director
Nov 7, 2022 04:01PM Cara Therapeutics Reports Third Quarter 2022 Financial Results
Nov 7, 2022 04:01PM Cara Therapeutics Reports Third Quarter 2022 Financial Results
Nov 3, 2022 07:05AM Cara Therapeutics (CARA) Appoints Lisa von Moltke to its Board
Nov 3, 2022 07:00AM Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
Nov 3, 2022 07:00AM Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
View Older Stories